4 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
Follow GVHD: new trials by email Literature Review of GVHD trials Research Report on GVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Safety and Efficacy of Treg Cell in the Treatment of GVHD Regulator T Cells - GVHD | Phase 1 / Phase 2 | Not yet recruiting | Xuzhou Medical University | 20 | 2024-06-01 | 2024-05-13 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease BMS-986004, Sirolimus, Tacrolimus - Graft-versus-host-disease, GVHD | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2019-02-15 | 2026-04-02 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Pacritinib, Sirolimus, Tacrolimus - Graft Vs Host Disease, GVHD | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 40 | 2017-06-08 | 2026-04-02 |
| Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) Brentuximab Vedotin - Graft-vs-Host Disease, GVHD | Phase 1 | Terminated | Massachusetts General Hospital | 19 | 2013-10-01 | 2018-07-26 |
| Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease Human umbilical cord blood-derived mesenchymal stem cells - Graft-Versus-Host Disease, GVHD | Phase 1 / Phase 2 | Unknown | Samsung Medical Center | 30 | 2012-01-01 | 2012-03-16 |
Graft vs Host Disease (7) · Leukemia, Myelomonocytic, Chronic (3) · Myelodysplastic Syndromes (3) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bronchiolitis Obliterans Syndrome (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Myeloproliferative Disorders (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Immune System Diseases (7) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2)
Sirolimus (3) · Tacrolimus (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Brentuximab Vedotin (1) · Cyclophosphamide (1) · Melphalan (1) · Mycophenolic Acid (1) · Standard of Care (1) · Tyrosine Kinase Inhibitors (1) · fludarabine (1) · fludarabine phosphate (1) · itolizumab (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · Biocon Limited (1) · Massachusetts General Hospital (1) · Samsung Medical Center (1) · Stanford University (1) · Tr1X, Inc. (1) · Xuzhou Medical University (1) · Zachariah Michael DeFilipp (1)
United States (7) · South Korea (1)
Farhad Khimani, M.D. (1) · Joel Rothman (1) · Joseph Pidala, M.D. (1) · Maria Grazia Roncarolo, MD (1) · Vanessa Kennedy, MD (1) · Yi-Bin Chen, MD (1) · Zachariah DeFilipp, MD (1)
PMID 28473406, PMID 29382747, PMID 33753457, PMID 35484649, PMID 42495646
R01HL133823 (1)